Regenerative medicine
for hospital systems
Arvix Biologics is a regenerative medicine company focused on developing and supporting biologic matrices designed for clinical care within hospital systems.
Built for institutional adoption
Arvix Biologics operates with a platform-based approach, emphasizing regulatory alignment, quality systems, and documentation readiness to support institutional evaluation and adoption.
The company's product portfolio includes placental-derived amniotic membranes and collagen-based wound matrices, developed within a unified regulatory and quality framework.
Arvix Biologics serves hospitals, ambulatory surgery centers, and clinical teams seeking consistent, well-documented regenerative solutions aligned with hospital workflows and compliance requirements.
Designed for hospital evaluation
Arvix Biologics develops products and documentation with hospital value analysis committees, procurement teams, and clinical stakeholders in mind.
Documentation Readiness
Comprehensive materials addressing regulatory status, processing methods, quality controls, and traceability to facilitate committee review.
Regulatory Clarity
Clear positioning within the HCT/P 361 regulatory framework with transparent documentation of processing and quality standards.
Institutional Support
Responsive support for hospital stakeholders throughout evaluation, contracting, onboarding, and implementation processes.
Platform Approach
Multiple product configurations within a unified quality and regulatory framework to support standardization and procurement efficiency.
Supply Consistency
Reliable supply chain and quality systems designed to support ongoing hospital relationships and clinical program development.
Workflow Integration
Products designed for predictable clinical handling and integration into existing hospital workflows and procurement models.
Commitment to quality and compliance
Arvix Biologics maintains comprehensive quality systems designed to support consistent product manufacturing, traceability, and regulatory compliance.
Quality Management Systems
Established quality systems aligned with current Good Tissue Practice (cGTP) requirements and industry standards.
Traceability & Documentation
Comprehensive donor screening, tissue tracking, and lot-level documentation to support institutional requirements.
Processing Standards
Validated processing methods designed to preserve tissue architecture while ensuring safety and consistency.
Regulatory Positioning
Products positioned as HCT/Ps regulated under Section 361 with clear documentation of regulatory status.
Supporting clinical care through regenerative solutions
Arvix Biologics is committed to developing biologic matrices that support hospital clinical programs with consistency, documentation readiness, and regulatory clarity. The company works to provide institutional stakeholders with the information and support needed to evaluate, adopt, and integrate regenerative solutions into their clinical workflows.